tiprankstipranks

CSPC Pharmaceutical Group Reports Decline in Q1 2025 Results Amid Industry Challenges

Story Highlights
CSPC Pharmaceutical Group Reports Decline in Q1 2025 Results Amid Industry Challenges

Don’t Miss TipRanks’ Half-Year Sale

CSPC Pharmaceutical Group ( (HK:1093) ) has issued an announcement.

CSPC Pharmaceutical Group reported a significant decline in its quarterly financial results for the three months ended March 31, 2025. The company’s total revenue decreased by 21.9% compared to the previous year, primarily due to a 27.3% drop in finished drug sales, impacted by industry policies such as centralized procurement and drug price adjustments. Despite this, the bulk products segment saw a 14.6% revenue increase, driven by higher demand and prices for vitamin C products. The company has been actively promoting product internationalization and out-licensing initiatives, which have contributed to a rise in license fee income, partially offsetting the decline in drug sales and providing potential future growth.

The most recent analyst rating on (HK:1093) stock is a Buy with a HK$6.21 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.

More about CSPC Pharmaceutical Group

CSPC Pharmaceutical Group Limited is a Hong Kong-based company operating in the pharmaceutical industry. It focuses on the production and sale of finished drugs, bulk products, and functional foods, with a market emphasis on therapeutic areas such as the nervous system, oncology, and anti-infectives.

Average Trading Volume: 154,577,597

Technical Sentiment Signal: Buy

Current Market Cap: HK$79.34B

See more data about 1093 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1